{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(1)"],"submitter":["Ksienski D"],"pubmed_abstract":["<h4>Background</h4>We investigated the association of peripheral blood inflammatory markers with overall survival (OS) in pembrolizumab treated advanced non-small cell lung cancer (aNSCLC) patients with programmed death ligand 1 (PD-L1) expression ≥50%. Clinical risk factors for development of immune-related adverse events (irAE) were also explored.<h4>Methods</h4>aNSCLC patients with high PD-L1 expression receiving pembrolizumab monotherapy outside of clinical trials were identified retrospectively. All patients were treated at one of six British Columbia Cancer clinics between August 2017 and June 2019. Patients were dichotomized using baseline neutrophil-to-lymphocyte ratio (NLR, </≥6.4) and platelet-to-lymphocyte ratio (PLR, </≥441.8). Factors associated with OS were assessed with Cox "],"journal":["Translational lung cancer research"],"pagination":["355-367"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7867765"],"repository":["biostudies-literature"],"pubmed_title":["Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab."],"pmcid":["PMC7867765"],"pubmed_authors":["Freeman AT","Clarkson M","Irons S","Ksienski D","Chan A","Croteau NS","Alex D","Wai ES","Patterson T","Poonja Z","Fiorino L","Lesperance M","Fenton D"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab.","description":"<h4>Background</h4>We investigated the association of peripheral blood inflammatory markers with overall survival (OS) in pembrolizumab treated advanced non-small cell lung cancer (aNSCLC) patients with programmed death ligand 1 (PD-L1) expression ≥50%. Clinical risk factors for development of immune-related adverse events (irAE) were also explored.<h4>Methods</h4>aNSCLC patients with high PD-L1 expression receiving pembrolizumab monotherapy outside of clinical trials were identified retrospectively. All patients were treated at one of six British Columbia Cancer clinics between August 2017 and June 2019. Patients were dichotomized using baseline neutrophil-to-lymphocyte ratio (NLR, </≥6.4) and platelet-to-lymphocyte ratio (PLR, </≥441.8). Factors associated with OS were assessed with Cox ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2025-04-26T18:34:07.159Z","creation":"2025-02-19T01:41:36.946Z"},"accession":"S-EPMC7867765","cross_references":{"pubmed":["33569318"],"doi":["10.21037/tlcr-20-541"]}}